文献速递前列腺癌

多参数磁共振与经会阴前列腺穿刺活检对前列腺癌诊断准确性的单中心评估

A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
PubMed 文献 · J Urol · 2018-03-01

单中心研究比较经直肠超声引导穿刺和多参数磁共振(mpMRI)以经会阴前列腺穿刺活检为参考标准的诊断性能,纳入426例患者。mpMRI诊断显著前列腺癌的ROC AUC为0.754,灵敏度87.0%,特异度55.3%,阴性预测值97.1%,但部分ISUP 2级癌症仍被漏诊。

要点

  • mpMRI诊断显著前列腺癌的AUC为0.754,灵敏度87.0%,特异度55.3%。
  • mpMRI阴性预测值97.1%,可减少不必要穿刺,但ISUP 2级癌症仍可能漏诊。
  • 经直肠超声引导穿刺低估了94例良性患者中的前列腺癌和95例高级别癌症。

核心结论

  • mpMRI是比经直肠超声引导穿刺更准确的前列腺癌诊断方法。
  • 但相当比例的ISUP Grade Group 2前列腺癌在mpMRI后仍未被检出。

研究设计与样本

  • 单中心研究,2012年4月至2016年1月纳入426例患者。
  • 患者先接受系统12针经直肠超声引导穿刺,3个月后行1.5T mpMRI。
  • 由两名对经会阴穿刺活检结果不知情的泌尿放射专科医生分配PI-RADS评分。
  • 以5mm间隔采样的经会阴前列腺穿刺活检(mpMRI后6个月内进行)为参考标准。

主要发现

  • 经直肠超声引导穿刺检出247/426例前列腺癌,179/426例良性组织学。
  • 经会阴穿刺活检检出321/426例前列腺癌。
  • 经直肠超声引导穿刺良性的179例中,94例经会阴穿刺检出前列腺癌。
  • 经直肠超声引导穿刺检出前列腺癌的247例中,95例经会阴穿刺检出更高级别癌症。
  • 以PI-RADS≥3检测显著前列腺癌(经会阴穿刺任一针Gleason 4+3或更高),ROC AUC为0.754(95%CI 0.677-0.819),灵敏度87.0%(95%CI 77.3-97.0),特异度55.3%(95%CI 50.2-60.4),阴性预测值97.1%(95%CI 94.8-99.4)。

关键数值与推荐

  • 显著前列腺癌定义为经会阴穿刺活检任一针含Gleason 4+3或更高。
  • mpMRI PI-RADS评分≥3用于检测显著前列腺癌。

临床怎么用

  • mpMRI可用于避免部分ISUP Grade Group 3或以上前列腺癌患者的不必要穿刺。
  • 在较宽松的显著癌症定义下,mpMRI后仍有相当比例前列腺癌未被检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study we evaluated the diagnostic performance of transrectal ultrasound guided biopsy and multiparametric magnetic resonance imaging to detect prostate cancer against transperineal prostate mapping biopsy as the reference test. MATERIALS AND METHODS: Transrectal ultrasound guided biopsy, multiparametric magnetic resonance imaging and transperineal prostate mapping biopsy were performed in 426 patients between April 2012 and January 2016. Patients initially underwent systematic 12 core transrectal ultrasound guided biopsy followed 3 months later by 1.5 Tesla, high resolution T2, diffusion-weighted, dynamic contrast enhanced multiparametric magnetic resonance imaging. Two specialist uroradiologists blinded to the results of transperineal prostate mapping biopsy allocated a PI-RADS™ (Prostate Imaging-Reporting and Data System) score to each multiparametric magnetic resonance imaging study. Transperineal prostate mapping biopsy with 5 mm interval sampling, which was performed within 6 months of multiparametric magnetic resonance imaging, served as the reference test. RESULTS: Transrectal ultrasound guided biopsy identified 247 of 426 patients with prostate cancer and 179 of 426 with benign histology. Transperineal prostate mapping biopsy detected prostate cancer in 321 of 426 patients. On transperineal prostate mapping biopsy 94 of 179 patients with benign transrectal ultrasound guided biopsy had prostate cancer and 95 of 247 with prostate cancer on transrectal ultrasound guided biopsy were identified with cancer of higher grade. Using a multiparametric magnetic resonance imaging PI-RADS score of 3 or greater to detect significant prostate cancer, defined as any core containing Gleason 4 + 3 or greater prostate cancer on transperineal prostate mapping biopsy, the ROC AUC was 0.754 (95% CI 0.677-0.819) with 87.0% sensitivity (95% CI 77.3-97.0), 55.3% specificity (95% CI 50.2-60.4) and 97.1% negative predictive value (95% CI 94.8-99.4). CONCLUSIONS: Multiparametric magnetic resonance imaging is a more accurate diagnostic test than transrectal ultrasound guided biopsy. However, a significant proportion of ISUP (International Society of Urological Pathology) Grade Group 2 prostate cancer remained undetected following multiparametric magnetic resonance imaging. Although multiparametric magnetic resonance imaging could avoid unnecessary biopsy in many patients with ISUP Grade Group 3 or greater prostate cancer, at less stringent definitions of significant cancer a substantial proportion of prostate cancer would remain undetected after multiparametric magnetic resonance imaging.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pal RP, Ahmad R, Trecartan S, et al. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy. J Urol. 2018. PMID: 29477717. doi:10.1016/j.juro.2018.02.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。